Jan 5, 2024, 17:31
Summary of 10 new indications/approvals in Heme Malignancies by FDA Oncology in 2023 – Oncology Brothers
Quoting Oncology Brothers on X/Twitter:
“Summary of 10 new indications/approvals in Heme Malignancies (excluding CART) by FDA Oncology in 2023:
1. Zanubrutinib
2. Pirtobrutinib
3. Polatuzumab
4. Epcortimab
5. Glofitamab
6. Quizartinib
7. Talquetamab
8. Elranatamab
9. Ivosidenib”
Source: Oncology Brothers/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18